Bioresponsive Mesoporous Silica Nanoparticles for Triggered Drug Release

被引:311
作者
Singh, Neetu [1 ,2 ]
Karambelkar, Amrita [3 ]
Gu, Luo [4 ]
Lin, Kevin [2 ,3 ]
Miller, Jordan S. [5 ]
Chen, Christopher S. [5 ]
Sailor, Michael J. [4 ]
Bhatia, Sangeeta N. [1 ,2 ,6 ,7 ]
机构
[1] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA
[2] David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
[3] MIT, Dept Chem Engn, Cambridge, MA 02139 USA
[4] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[5] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA
[6] Brigham & Womens Hosp, Div Med, Boston, MA 02115 USA
[7] Howard Hughes Med Inst, Cambridge, MA 02139 USA
关键词
RESPONSIVE CONTROLLED-RELEASE; DELIVERY-SYSTEM; IN-VITRO; NANOTECHNOLOGY;
D O I
10.1021/ja206998x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Mesoporous silica nanoparticles (MSNPs) have garnered a great deal of attention as potential carriers for therapeutic payloads. However, achieving triggered drug release from MSNPs in vivo has been challenging. Here, we describe the synthesis of stimulus-responsive polymer-coated MSNPs and the loading of therapeutics into both the core and shell domains. We characterize MSNP drug-eluting properties in vitro and demonstrate that the polymer-coated MSNPs release doxorubicin in response to proteases present at a tumor site in vivo, resulting in cellular apoptosis. These results demonstrate the utility of polymer-coated nanoparticles in specifically delivering an antitumor payload.
引用
收藏
页码:19582 / 19585
页数:4
相关论文
共 37 条
[1]   Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity [J].
Albright, CF ;
Graciani, N ;
Han, W ;
Yue, E ;
Stein, R ;
Lai, ZH ;
Diamond, M ;
Dowling, R ;
Grimminger, L ;
Zhang, SY ;
Behrens, D ;
Musselman, A ;
Bruckner, R ;
Zhang, MZ ;
Jiang, X ;
Hu, D ;
Higley, A ;
DiMeo, S ;
Rafalski, M ;
Mandlekar, S ;
Car, B ;
Yeleswaram, S ;
Stern, A ;
Copeland, RA ;
Combs, A ;
Seitz, SP ;
Trainor, GL ;
Taub, R ;
Huang, P ;
Oliff, A .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) :751-760
[2]  
Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]
[3]   Active targeting schemes for nanoparticle systems in cancer therapeutics [J].
Byrne, James D. ;
Betancourt, Tania ;
Brannon-Peppas, Lisa .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (15) :1615-1626
[4]   In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line [J].
Chang, Jenq-Sheng ;
Chang, Ke Liang B. ;
Hwang, Deng-Fwu ;
Kong, Zwe-Ling .
ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2007, 41 (06) :2064-2068
[5]   Remarkably enhanced stability and function of core/shell nanoparticles composed of a lecithin core and a pluronic shell layer by photo-crosslinking the shell layer: In vitro and in vivo study [J].
Choi, Won Il ;
Yoon, Kyung Chul ;
Im, Seong Kyu ;
Kim, Young Ha ;
Yuk, Soon Hong ;
Tae, Giyoong .
ACTA BIOMATERIALIA, 2010, 6 (07) :2666-2673
[6]   To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery [J].
Danhier, Fabienne ;
Feron, Olivier ;
Preat, Veronique .
JOURNAL OF CONTROLLED RELEASE, 2010, 148 (02) :135-146
[7]   Impact of Nanotechnology on Drug Delivery [J].
Farokhzad, Omid C. ;
Langer, Robert .
ACS NANO, 2009, 3 (01) :16-20
[8]   pH-Responsive Drug Release from Polymer-Coated Mesoporous Silica Spheres [J].
Gao, Qiang ;
Xu, Yao ;
Wu, Dong ;
Sun, Yuhan ;
Li, Xiaoan .
JOURNAL OF PHYSICAL CHEMISTRY C, 2009, 113 (29) :12753-12758
[9]   In vivo Biodistribution and Urinary Excretion of Mesoporous Silica Nanoparticles: Effects of Particle Size and PEGylation [J].
He, Qianjun ;
Zhang, Zhiwen ;
Gao, Fang ;
Li, Yaping ;
Shi, Jianlin .
SMALL, 2011, 7 (02) :271-280
[10]   The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses [J].
He, Qianjun ;
Zhang, Jiamin ;
Shi, Jianlin ;
Zhu, Ziyan ;
Zhang, Linxia ;
Bu, Wenbo ;
Guo, Limin ;
chen, Yu .
BIOMATERIALS, 2010, 31 (06) :1085-1092